Annovis Issued Patent for Method of Treating Parkinson’s Disease & Other Lewy Body Diseases
Annovis Bio Inc. was recently issued a patent (US 10,383,851) in August 2019 for a method of treating Parkinson’s disease, Lewy body dementia, and other Lewy body diseases in humans by administering its lead compound, ANVS401. The company expects multiple patents to be generated from this patent family, each targeting specific neurodegenerative diseases independently.
Maria Maccecchini, PhD, CEO of Annovis, said “Based on discussions with the patent office, we have filed additional patent applications for each individual neurodegenerative disease that our drug targets. We plan to provide further updates as we execute on this process.”
ANVS401 improves axonal transport, the information highway of the nerve cell, by attacking multiple neurotoxic proteins simultaneously. ANVS401 is the lead compound in the company’s ongoing Phase 2a clinical trial for Alzheimer’s disease and in a planned Phase 2a trial for Parkinson’s disease.
The company is planning a 50-patient Phase 2a study in Parkinson’s disease with primary endpoints targeting a decrease in neurotoxic protein levels, increase in neurotransmitters and neurotrophic factors, lowering of inflammatory proteins, lowering of neurodegeneration markers, and positive cognitive and functional outcomes.
“We believe we have a novel solution to stop the course of Parkinson’s disease and Alzheimer’s disease, areas of unmet need valued in the multibillions of dollars and growing,” continued Dr. Maccecchini. “The successful completion of our two Phase 2a studies will provide optimal information on target and pathway engagement in both diseases and allow us to move into pivotal studies.”
Parkinson’s disease affects an estimated 1 million people in the US and as many as 10 million globally. An estimated 5.8 million people in the US have Alzheimer’s disease, and there are approximately 44 million people worldwide living with the disease.
Headquartered in Berwyn, PA, Annovis Bio, Inc. is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and Alzheimer’s in Down Syndrome (AD-DS). We believe that we are the only company developing a drug for AD, PD, and AD-DS that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. We expect our treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. We have an ongoing Phase 2a study in AD patients and plan to commence a second Phase 2a study in PD patients. For more information, visit www.annovisbio.com.
Total Page Views: 955
